XETRA - Delayed Quote EUR
Valneva SE (AYJ.DE)
At close: October 18 at 5:35 PM GMT+2
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Total Revenue
150,782.0000
153,712.0000
361,303.0000
348,085.0000
110,321.0000
--
Cost of Revenue
92,665.0000
100,875.0000
324,441.0000
187,920.0000
54,302.0000
--
Gross Profit
58,117.0000
52,837.0000
36,862.0000
160,165.0000
56,019.0000
--
Operating Expense
150,212.0000
134,949.0000
150,236.0000
221,514.0000
111,140.0000
--
Operating Income
-92,095.0000
-82,112.0000
-113,374.0000
-61,349.0000
-55,121.0000
--
Net Non Operating Interest Income Expense
-24,935.0000
-22,115.0000
-18,794.0000
-16,714.0000
-10,620.0000
--
Other Income Expense
91,042.0000
5,598.0000
-12,648.0000
8,083.0000
437.0000
--
Pretax Income
-25,987.0000
-98,629.0000
-144,815.0000
-69,979.0000
-65,302.0000
--
Tax Provision
6,420.0000
2,800.0000
-1,536.0000
3,446.0000
-909.0000
--
Net Income Common Stockholders
-32,407.0000
-101,429.0000
-143,279.0000
-73,425.0000
-64,393.0000
--
Diluted NI Available to Com Stockholders
-32,407.0000
-101,429.0000
-143,279.0000
-73,425.0000
-64,393.0000
--
Basic EPS
-0.23
-0.73
-1.24
-0.75
-0.71
--
Diluted EPS
-0.24
-0.73
-1.24
-0.75
-0.71
--
Basic Average Shares
136,484.3810
138,943.8360
115,547.5810
97,619.3200
90,757.1730
--
Diluted Average Shares
139,315.7140
138,943.8360
115,547.5810
97,619.3200
90,757.1730
--
Total Operating Income as Reported
-458.0000
-82,087.0000
-113,443.0000
-61,390.0000
-55,120.0000
--
Total Expenses
242,877.0000
235,824.0000
474,677.0000
409,434.0000
165,442.0000
--
Net Income from Continuing & Discontinued Operation
-32,407.0000
-101,429.0000
-143,279.0000
-73,425.0000
-64,393.0000
--
Normalized Income
-100,688.5000
-105,627.5000
-130,756.2482
-79,369.6800
-64,955.0656
--
Interest Income
1,493.0000
1,210.0000
260.0000
249.0000
119.0000
--
Interest Expense
26,428.0000
23,325.0000
19,054.0000
16,963.0000
10,739.0000
--
Net Interest Income
-24,935.0000
-22,115.0000
-18,794.0000
-16,714.0000
-10,620.0000
--
EBIT
441.0000
-75,304.0000
-125,761.0000
-53,016.0000
-54,563.0000
--
EBITDA
18,964.0000
-57,720.0000
-104,725.0000
-38,735.0000
-44,764.0000
--
Reconciled Cost of Revenue
92,665.0000
100,875.0000
324,441.0000
187,920.0000
54,302.0000
--
Reconciled Depreciation
18,523.0000
17,584.0000
21,036.0000
14,281.0000
9,799.0000
--
Net Income from Continuing Operation Net Minority Interest
-32,407.0000
-101,429.0000
-143,279.0000
-73,425.0000
-64,393.0000
--
Total Unusual Items Excluding Goodwill
91,042.0000
5,598.0000
-12,657.0000
8,088.0000
570.0000
--
Total Unusual Items
91,042.0000
5,598.0000
-12,657.0000
8,088.0000
570.0000
--
Normalized EBITDA
-72,078.0000
-63,318.0000
-92,068.0000
-46,823.0000
-45,334.0000
--
Tax Rate for Calcs
0.0003
0.0003
0.0000
0.0003
0.0000
--
Tax Effect of Unusual Items
22,760.5000
1,399.5000
-134.2482
2,143.3200
7.9344
--
12/31/2019 - 5/7/2010
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
T5O0.DE bioXXmed AG
3.1500
-9.74%
BIO3.DE Biotest Aktiengesellschaft
27.70
0.00%
88Q.DE 4basebio PLC
16.20
0.00%
BIO.DE Biotest Aktiengesellschaft
41.80
+0.48%
7V0.DE Darwin AG
31.40
+5.37%
PSH.DE Sernova Corp.
0.1748
-0.63%
NVV1.BE Novavax Inc
9.39
+1.00%
VX1.DE Vertex Pharmaceuticals Incorporated
447.30
-0.38%
HPHA.DE Heidelberg Pharma AG
2.6700
+4.71%
FYB.DE Formycon AG
52.90
+1.73%